{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:52:16Z","timestamp":1787007136892,"version":"build-2736575974"},"reference-count":84,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 22595461, 82373725"],"award-info":[{"award-number":["No. 22595461, 82373725"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["No.2021041171"],"award-info":[{"award-number":["No.2021041171"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Suzhou International Joint Laboratory for Diagnosis and Treatment of Brain Diseases and Science and Technology Program of Suzhou","award":["No. SKY20221035"],"award-info":[{"award-number":["No. SKY20221035"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,4,3]]},"DOI":"10.1080\/13543776.2026.2636040","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T14:51:37Z","timestamp":1771599097000},"page":"311-332","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["LSD1 inhibitors for anticancer therapy: an updated patent review (2022\u20132025)"],"prefix":"10.1080","volume":"36","author":[{"given":"Zhoudong","family":"Zhang","sequence":"first","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyu","family":"Li","sequence":"additional","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zitong","family":"Wang","sequence":"additional","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Zhou","sequence":"additional","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolu","family":"Xiong","sequence":"additional","affiliation":[{"name":"Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University","place":["Nanjing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Hou","sequence":"additional","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanqiu","family":"Li","sequence":"additional","affiliation":[{"name":"Soochow University","place":["Suzhou, China"]},{"name":"Jiangsu Province Engineering Research Center of Molecular Target Therapy and Companion Diagnostics in Oncology","place":["Suzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,2,26]]},"reference":[{"key":"e_1_3_6_3_1","doi-asserted-by":"publisher","DOI":"10.4137\/GEG.S32160"},{"key":"e_1_3_6_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature05919"},{"key":"e_1_3_6_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-0077-5"},{"key":"e_1_3_6_6_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.1232504"},{"key":"e_1_3_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2004.12.012"},{"key":"e_1_3_6_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1947601911417976"},{"key":"e_1_3_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217093"},{"key":"e_1_3_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature06092"},{"key":"e_1_3_6_11_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1214675"},{"key":"e_1_3_6_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa058"},{"key":"e_1_3_6_13_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.616185"},{"key":"e_1_3_6_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3959-9"},{"key":"e_1_3_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.014"},{"key":"e_1_3_6_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2020.105335"},{"key":"e_1_3_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002548"},{"key":"e_1_3_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2109332"},{"key":"e_1_3_6_19_1","unstructured":"Jubilant therapeutics initiates clinical trials for JBI-802 and JBI-778 in Oncology. 2024 [cited 2025 Dec 25]. Available from: https:\/\/trial.medpath.com"},{"key":"e_1_3_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.01.005"},{"key":"e_1_3_6_21_1","unstructured":"Sava J. FDA clears investigational new drug application for REC-4539 in SCLC. 2025 [cited 2025 Dec 25]. Available from: https:\/\/www.targetedonc.com"},{"key":"e_1_3_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2006.07.012"},{"key":"e_1_3_6_23_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00919"},{"key":"e_1_3_6_24_1","doi-asserted-by":"publisher","DOI":"10.1021\/ja101557k"},{"key":"e_1_3_6_25_1","unstructured":"Yu B. Preparation of phenylcyclopropylamine compounds as LSD1 inhibitor. CN117164465 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_26_1","unstructured":"Yu B Song Y Zhang J et al. Dipeptide compound its preparation method and application as LSD1 inhibitor. CN116284214 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_27_1","unstructured":"Sun K Liu Y Zheng Y et al. Phencyclidine compound its preparation method and application in preparation of LSD1 target-based inhibitor and antitumor drug. CN116283821 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_28_1","unstructured":"Li Z Yuan Y Ma J et al. Preparation of pyrimidine-TCP compounds as antitumor drug. CN115710275 A. Henan University of Chinese Medicine; 2023."},{"key":"e_1_3_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115321"},{"key":"e_1_3_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115228"},{"key":"e_1_3_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117438"},{"key":"e_1_3_6_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fitote.2017.05.001"},{"key":"e_1_3_6_33_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1601017"},{"key":"e_1_3_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2022.114410"},{"key":"e_1_3_6_35_1","unstructured":"Liu H Dai X Zhou Y et al. Preparation of quinazoline compounds as LSD1 inhibitors and its application in preparation of anti-tumor drugs targeting LSD1. CN116836121 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2021.113778"},{"key":"e_1_3_6_37_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c00972"},{"key":"e_1_3_6_38_1","unstructured":"Sun H Wang N. Nanjing Jieyin diagnostic Technology Co. Ltd. Application of dacomitinib as LSD1 inhibitor in medicine for resisting Ewing sarcoma. CN118662513 A. 2024."},{"key":"e_1_3_6_39_1","unstructured":"Zhi Y Zhang X Li X et al. Preparation of substituted quinoxaline derivatives and its applications. CN119285613 A. Henan University of Chinese Medicine; 2025."},{"key":"e_1_3_6_40_1","unstructured":"Ma Q Duan Z Li Y et al. Preparation of quinazoline compounds as LSD1 inhibitor. CN119285605 A. Henan University of Chinese Medicine; 2025."},{"key":"e_1_3_6_41_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02017"},{"key":"e_1_3_6_42_1","unstructured":"Xue D Xu T Huang J et al. Tencent Technology (Shenzhen) Co. Ltd. Preparation of imidazo[1 2-a]pyrazine or pyrazolo[1 5-a]pyrimidine derivatives as LSD1 inhibitors for treating cancer. CN116836167 A. 2023."},{"key":"e_1_3_6_43_1","unstructured":"Xue D Huang J Xu T et al. Tencent Technology (Shenzhen) Co. Ltd. Pyrrolo[2 3-d]pyrimidine or pyrazolo[3 4-d]pyrimidine derivative and use thereof. CN117003754 A. 2023."},{"key":"e_1_3_6_44_1","unstructured":"Yu B. Imidazo[1 2-c] pyrimidine compound and preparation method and application thereof. CN117069727 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_45_1","unstructured":"Xiong B Li J Liu T et al. Preparation of pyrrolopyridine compounds compositions thereof and its application in medicine. CN119431358 A. Shanghai Institute of Materia Medica Chinese Academy of Sciences; 2025."},{"key":"e_1_3_6_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115684"},{"key":"e_1_3_6_47_1","unstructured":"Liu H Dai X Xiong X et al. Acridine compound and its preparation method and application in preparation of antitumor drug based on LSD1 target. CN114805205 A. Zhengzhou University; 2022."},{"key":"e_1_3_6_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115255"},{"key":"e_1_3_6_49_1","unstructured":"Ma M Fang Y. Preparation of phenoxazine derivatives as antitumor agents. CN119707853 A. University of Science and Technology of China; 2025."},{"key":"e_1_3_6_50_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01593"},{"key":"e_1_3_6_51_1","unstructured":"Rienhoff H Celatka C Tapper A et al. Imago biosciences Inc. Pyrazole derivatives as KDM1A inhibitors for the treatment of disease and their preparation. WO2023069884. 2023."},{"key":"e_1_3_6_52_1","unstructured":"Liu C Ma Z Xiang Y et al. Preparation of pyrazole derivatives and its application in preparation of drugs for preventing or treating (LSD1)-mediated diseases. CN116768797 A. Chengdu Easton Biopharmaceuticals Co. Ltd.; 2023."},{"key":"e_1_3_6_53_1","unstructured":"Liu C Ma Z Xiang Y et al. Chengdu Easton Biopharmaceuticals Co. Ltd. Process fro preparation of pyridine derivative and use thereof. WO2023142641. 2023."},{"key":"e_1_3_6_54_1","unstructured":"Du B Jiang W Yang N et al. Chengdu Easton Biopharmaceuticals Co. Ltd. Preparation of an isonicotinonitrile compound used as LSD1 inhibitor. CN118994109 A. 2024."},{"key":"e_1_3_6_55_1","unstructured":"Wang L Gu H Xian X et al. Chengdu Easton Biopharmaceuticals Co. Ltd. Preparation of an isonicotinitrile compound crystal used as LSD1 inhibitor. CN118994108 A. 2024."},{"key":"e_1_3_6_56_1","unstructured":"He D Qiao Z Gong C et al. Chengdu Shuode Pharmaceutical Co. Ltd. Preparation method of drug compositions of pyridine derivatives and application in drugs for the treatment of LSD1-mediated diseases. CN117582438 A. 2024."},{"key":"e_1_3_6_57_1","unstructured":"Yu B Song Y. Preparation of 4-(3-indolyl)-1 3-thiazole compounds with alicyclic ring system and aniline. CN116768881 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_58_1","unstructured":"Zhao B Ma L Yang F et al. Preparation of ((phenylcarbamoyl\/arylcarbamoylaminoethyl)methyltriazolyl)methyl carbodithioates as LSD1 inhibitors. CN117658932 A. Zhengzhou University; 2024."},{"key":"e_1_3_6_59_1","unstructured":"Zheng Y Dai X Ji S et al. S-triazine-based LSD1 inhibitor and its preparing method and application. CN117946018 A. Zhengzhou University; 2024."},{"key":"e_1_3_6_60_1","unstructured":"Hu B Liu P Zhang M et al. Preparation of heteroaromatic ketones as LSD1 inhibitors. CN118772110 A. Shanghai Fosun Pharmaceutical (Group) Co. Ltd.; 2024."},{"key":"e_1_3_6_61_1","unstructured":"Sun K Liu Y Zheng Y et al. Preparation of thiazolidinedione derivatives and its application in preparation of LSD1-based inhibitors or antitumor drugs. CN116354901 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_62_1","unstructured":"Culurgioni S Besnard J Bradley A et al. Exscientia AI limited. Preparation of substituted biphenylcarbonitriles as LSD1 modulators. WO2024141757. 2024."},{"key":"e_1_3_6_63_1","unstructured":"Packiarajan M Wang Y White AD et al. The regents of the University of Michigan. Preparation of oxygenated heterocyclic LSD-1 inhibitors for treatment of LSD-1-related disorder. WO2025072637. 2025."},{"key":"e_1_3_6_64_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2023.115516"},{"key":"e_1_3_6_65_1","unstructured":"Wu L Sun J Zhao L et al. Medshine Discovery Inc. N-(2-aminophenyl)benzamide compound and application. WO2023284651. 2023."},{"key":"e_1_3_6_66_1","unstructured":"Ma Y Su N Guan Y et al. Fuwai central China cardiovascular Hospital Henan University of animal husbandry and economy. Preparation of 3-arylindole derivatives as KDM1A\/HDACs dual-target inhibitors and its applications. CN116082216 A. 2023."},{"key":"e_1_3_6_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01524"},{"key":"e_1_3_6_68_1","unstructured":"Chen S Yan J Ding Z et al. Sichuan Huiyu Pharmaceutical Co. Ltd. Sichuan Huiyu Seacross Pharm Technol Co. Ltd. Hydroxyamide Derivative Application As HDAC LSD1 Inhibitor. WO2023222115. 2023."},{"key":"e_1_3_6_69_1","unstructured":"Sun K Yue L Ma R et al. Zhengzhou University. Preparation of ((aminopiperidinyl)(cyanophenyl)dihydropyrimidinylphenoxyalkyl)hydroxyacetamides as LSD1 and HDAC6 inhibitors. CN118619922 A. 2024."},{"key":"e_1_3_6_70_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.0c00978"},{"key":"e_1_3_6_71_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01098"},{"key":"e_1_3_6_72_1","unstructured":"Yu B Song Y. Indolepyrazoles with N-diformamido piperazine and N-methylpiperazinyl its preparation methods and applications. CN116768862 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_73_1","doi-asserted-by":"publisher","DOI":"10.4155\/fmc-2021-0292"},{"key":"e_1_3_6_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.117235"},{"key":"e_1_3_6_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2025.117879"},{"key":"e_1_3_6_76_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00267"},{"key":"e_1_3_6_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2020.02.006"},{"key":"e_1_3_6_78_1","unstructured":"Zhao W Huang L Huang M et al. Preparation of fluorine-containing trans phenyl cyclopropylamine derivatives as LSD1 inhibitors for myocardial fibrosis and cancer treatment. CN118255686 A. Zhengzhou University; 2024."},{"key":"e_1_3_6_79_1","unstructured":"Huang L Huang M. Pyrimidine-triazole-fluoro substituted phenyl cyclopropylamine derivatives and its application in treating acute myeloid leukemia. CN118164965 A. Zhengzhou University; 2024."},{"key":"e_1_3_6_80_1","unstructured":"Cheng M Wang J Wang M et al. Aromatic six-membered ring-fused imidazole derivative and preparation method therefor and use thereof. WO2023236820. Shenyang Pharmaceutical University; 2023."},{"key":"e_1_3_6_81_1","unstructured":"Wu L Zhan Z Zhao L et al. Medshine Discovery Inc. Preparation of thiophene compounds for treating LSD1-related diseases. WO2022188709. 2022."},{"key":"e_1_3_6_82_1","unstructured":"Sun K Ma L Zheng Y et al. Preparation of phenylpiperazine compounds as LSD1 target-based inhibitors or antitumor drugs. CN116640106 A. Zhengzhou University; 2023."},{"key":"e_1_3_6_83_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c00966"},{"key":"e_1_3_6_84_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c01250"},{"key":"e_1_3_6_85_1","unstructured":"Yu B Ma T Dai M. Medical use of ailanthone in LSD1 protein degradation agent. CN119280223 A. Zhengzhou University; 2025."},{"key":"e_1_3_6_86_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.4c02277"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2636040","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T10:34:51Z","timestamp":1775039691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2636040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,26]]},"references-count":84,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,3]]}},"alternative-id":["10.1080\/13543776.2026.2636040"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2636040","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,26]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}